Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Dec 16;13(3):1024-1029.
doi: 10.1159/000527672. eCollection 2022 Sep-Dec.

Preserflo Microshunt Surgery for Ocular Hypertension following Intravitreal Fluocinolone Acetonide Implant Removal: A Case Report

Amina Rezkallah  1   2 , Olivier Loria  1   2 , Thibaud Mathis  1   2 , Samuel Chacun  1 , Philippe Denis  1 , Laurent Kodjikian  1   2
Affiliations
Case Reports

Preserflo Microshunt Surgery for Ocular Hypertension following Intravitreal Fluocinolone Acetonide Implant Removal: A Case Report

Amina Rezkallah et al. Case Rep Ophthalmol. .

Abstract

Diabetic macular edema (DME) is now a well-known condition for which a number of treatments have been shown to be effective. Intraocular corticosteroids are part of this therapeutic arsenal but are sometimes responsible for ocular hypertension. We describe here the case of a 60-year-old man with a history of bilateral DME who received an intravitreal injection of 190 µg fluocinolone acetonide (FAc) (ILUVIEN®, Alimera Sciences, Alpharetta, GA, USA) who presented a persistent ocular hypertension in one eye despite FAc removal by pars plana vitrectomy and was successfully managed by Preserflo® microshunt surgery.

Keywords: Fluocinolone acetonide implant; Microinvasive bleb surgery; Steroid-induced ocular hypertension.

PubMed Disclaimer

Conflict of interest statement

Olivier Loria, Amina Rezkallah, and Samuel Chacun have no conflict of interest. Thibaud Mathis is a consultant for Abbvie, Bayer, GSK, Horus, and Novartis. Laurent Kodkijian is a consultant for Abbvie, Bayer, Horus, Novartis, Roche, and Thea. Philippe Denis is a consultant for Abbvie, Thea, Horus, and Santen.

References

    1. Campochiaro PA, Hafiz G, Shah SM, Bloom S, Brown DM, Busquets M, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology. 2010;117(7):1393–9.e3. 10.1016/j.ophtha.2009.11.024. - DOI - PubMed
    1. Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–32. 10.1016/j.ophtha.2012.04.030. - DOI - PubMed
    1. Mathis T, Papegaey M, Ricard C, Rezkallah A, Matonti F, Sudhalkar A, et al. Efficacy and safety of intravitreal fluocinolone acetonide implant for chronic diabetic macular edema previously treated in real-life practice: the REALFAc study. Pharmaceutics. 2022;14(4):723. 10.3390/pharmaceutics14040723. - DOI - PMC - PubMed
    1. Massin P, Erginay A, Dupas B, Couturier A, Tadayoni R. Efficacy and safety of sustained-delivery fluocinolone acetonide intravitreal implant in patients with chronic diabetic macular edema insufficiently responsive to available therapies: a real-life study. Clin Ophthalmol. 2016;10:1257–64. 10.2147/OPTH.S105385. - DOI - PMC - PubMed
    1. Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J; Medisoft Audit Group . Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study. Eye. 2022;36(5):1012–8. 10.1038/s41433-021-01542-w. - DOI - PMC - PubMed

Publication types